Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer

• Status: Completed
• Trial end date: 2017-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to determine the safety and highest tolerated dose of anti-OX40 in patients with advanced cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Providence Health & Services
• Treatments: Vaccines

Criteria

Inclusion Criteria:

• Patients with uncurable metastatic carcinoma, lymphoma, or sarcoma.

• ECOG performance status 0, 1, 2

• No active bleeding

• No clinical coagulopathy

• Anticipated lifespan greater than 12 weeks

Exclusion Criteria:

• Active residual toxicity from prior therapies

• Active Infection

• HIV positive

• Hepatitis B or C positive

• Pregnant or nursing women

• Requirement for oral steroids

• Brain metastases

• Presence or history of autoimmune disease

• Shellfish or tetanus allergy

• Splenomegaly

• Lymph nodes greater than 10 cm in maximal diameter

• Uncontrolled angina or class II or IV heart failure